Trial Profile
Pivotal phase III trial of FP 1097 in women with urinary incontinence or overactive bladder
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2011
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Registrational; Therapeutic Use
- 12 Jan 2011 New trial record